(Q38114143)

29 August 2017

A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening (English)

1 reference

prostate cancer screening

29 August 2017

1 reference

1 reference

Vishvas Garg

1

1 reference

29 August 2017

Ning Yan Gu

series ordinal

2

1 reference

29 August 2017

Matthew E Borrego

series ordinal

3

1 reference

29 August 2017

Dennis W Raisch

series ordinal

4

1 reference

29 August 2017

1 June 2013

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

29 August 2017

16

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

29 August 2017

13

1 reference

29 August 2017

327-342

1 reference

29 August 2017

3

1 reference

29 August 2017

Cancer statistics, 2013

1 reference

Lifetime economic burden of prostate cancer

21 January 2018

1 reference

Quality of life for men with prostate cancer.

21 January 2018

1 reference

Impact of cancer on health-related quality of life of older Americans

21 January 2018

1 reference

Selective estrogen receptor modulators for BPH: new factors on the ground.

21 January 2018

1 reference

Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

21 January 2018

1 reference

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer

21 January 2018

1 reference

Primary care providers' perspectives on discontinuing prostate cancer screening

21 January 2018

1 reference

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

21 January 2018

1 reference

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

21 January 2018

1 reference

Bias in published cost effectiveness studies: systematic review

21 January 2018

1 reference

Pharmaceutical company funding and its consequences: a qualitative systematic review

21 January 2018

1 reference

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.

21 January 2018

1 reference

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

21 January 2018

1 reference

Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial

21 January 2018

1 reference

Cost-effectiveness analysis of prostate cancer screening

21 January 2018

1 reference

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.

21 January 2018

1 reference

Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml

21 January 2018

1 reference

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

21 January 2018

1 reference

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

21 January 2018

1 reference

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

21 January 2018

1 reference

Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project

21 January 2018

1 reference

Screening for prostate cancer. A decision analytic view

21 January 2018

1 reference

A quantitative analysis of the costs and benefits of prostate cancer screening

21 January 2018

1 reference

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

21 January 2018

1 reference

Cost-effectiveness of Prostate Health Index for prostate cancer detection

21 January 2018

1 reference

Detection of latent prostate cancer from routine screening: comparison with breast cancer screening

21 January 2018

1 reference

Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics

21 January 2018

1 reference

The NICE cost-effectiveness threshold: what it is and what that means

21 January 2018

1 reference

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion

21 January 2018

1 reference

Clinical decisions. Prostate cancer screening--polling results

21 January 2018

1 reference

Quality-of-life effects of prostate-specific antigen screening.

21 January 2018

1 reference

Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.13.26

1 reference

29 August 2017

1 reference